ANALISIS TANGGUNG JAWAB HUKUM PRODUSEN TERHADAP KERUGIAN KONSUMEN AKIBAT PEREDARAN OBAT SIRUP YANG TIDAK MEMENUHI PERSYARATAN KEAMANAN (STUDI KASUS PUTUSAN NOMOR 771/Pdt.G/2022/PN.Jkt.Pst)

Authors

  • Fitria agustin Universitas Serang Raya, Kota Serang, Indonesia Author
  • Deasy Dharyanti Universitas Serang Raya, Kota Serang, Indonesia Author
  • Michael Javas Ramadhan Universitas Serang Raya, Kota Serang, Indonesia Author

DOI:

https://doi.org/10.71282/jurmie.v3i11.2706

Keywords:

consumer protection; manufacturers’ liability; syrup medicine; ethylene glycol; class action.

Abstract

The circulation of syrup medicines contaminated with ethylene glycol (EG) and diethylene glycol (DEG) in Indonesia in 2022 raised serious questions about product safety, manufacturers’ liability, and the effectiveness of consumer protection. This study aims to analyze the legal basis and forms of manufacturers’ responsibility for consumer losses caused by unsafe syrup medicines and to examine the role of class action in obtaining remedies, with particular attention to Central Jakarta District Court Decision Number 771/Pdt.G/2022/PN.Jkt.Pst. The study uses normative juridical legal research with statutory, case, and conceptual approaches. Primary legal materials include consumer protection and health legislation, relevant regulations of the Food and Drug Supervisory Agency (BPOM), and the class-action procedural regulation; secondary materials include legal and health journal articles, official BPOM publications, and World Health Organization materials. The materials are analyzed qualitatively through descriptive-analytical interpretation. The analysis indicates that manufacturers must ensure safety, efficacy, and quality throughout supplier selection, procurement, production, testing, and distribution. Articles 7, 8, 19, and 28 of the Consumer Protection Law provide the basis for duties and compensation, while Articles 1365 and 1366 of the Civil Code may apply where unlawful conduct or negligence, loss, and causation are established. Class action can facilitate collective redress, although individual losses require careful assessment. This study emphasizes an integrated approach combining preventive quality control, transparent product withdrawal, and evidence-based compensation. Its contribution lies in connecting product-safety obligations with collective remedies and differentiated consumer losses.

Downloads

Download data is not yet available.

References

Alzahrah, Aurelya Putri, dan Dwi Desi Yayi Tarina. 2025. “Legal Liability of Pharmaceutical Industry in Consumer Class Action Lawsuits: Analysis of Court Decision Number 771/Pdt.G/2022/PN Jkt.Pst.” Journal of Law, Politic and Humanities 6(1): 489–497. https://doi.org/10.38035/jlph.v6i1.2500.

Badan Pengawas Obat dan Makanan. 2022a. “Tindakan Tegas BPOM dan Bareskrim Polri terhadap Industri Farmasi Produsen Sirup Obat yang Tidak Memenuhi Standar dan/atau Persyaratan Keamanan, Khasiat, dan Mutu.” 1 November 2022. https://www.pom.go.id/siaran-pers/tindakan-tegas-bpom-dan-bareskrim-polri-terhadap-industri-farmasi-produsen-sirup-obat-yang-tidak-memenuhi-standar-dan-atau-persyaratan-keamanan-khasiat-dan-mutu.

Badan Pengawas Obat dan Makanan. 2022b. “Perkembangan Hasil Pengawasan Sirup Obat.” 10 November 2022. https://standar-otskk.pom.go.id/berita/perkembangan-hasil-pengawasan-sirup-obat.

Badan Pengawas Obat dan Makanan. 2022c. “Pencabutan Izin Edar Sirup Obat Produksi PT Yarindo Farmatama, PT Universal Pharmaceutical Industries, dan PT Afi Farma.” 6 November 2022. https://www.pom.go.id/penjelasan-publik/penjelasan-bpom-ri-nomor-hm-01-1-2-11-22-240-tanggal-6-november-2022-tentang-pencabutan-izin-edar-sirup-obat-produksi-pt-yarindo-farmatama-pt-universal-pharmaceutical-industries-dan-pt-afi-farma.

Kristiyanti, Celina Tri Siwi. 2008. Hukum Perlindungan Konsumen. Jakarta: Sinar Grafika.

Lubis, Achmad Raihansyah, dan Dwi Desi Yayi Tarina. 2023. “Perlindungan Hukum terhadap Konsumen Akibat Mengkonsumsi Obat Sirup yang Merusak Kesehatan.” Jurnal USM Law Review 6(3): 988–1004.

Marselina, Indri, dan Christin Septina Basani. 2025. “Putusan Gugatan Class Action pada Kasus Gagal Ginjal pada Anak dalam Perspektif Keadilan dan Pertanggungjawaban.” Rewang Rencang: Jurnal Hukum Lex Generalis 6(12).

Selviya. Tanpa tahun. “Peran Pengawasan BPOM terhadap Peredaran Obat Sirup yang Tercemar Etilen Glikol Ditinjau dari Hukum Perlindungan Konsumen.” Jurnal Fatwa Hukum, Universitas Tanjungpura.

Umar, Tungki Pratama, Nityanand Jain, dan Henri Azis. 2023. “Endemic Rise in Cases of Acute Kidney Injury in Children in Indonesia and Gambia: What Is the Likely Culprit and Why?” Kidney International 103(3): 444–447. https://doi.org/10.1016/j.kint.2022.12.004.

World Health Organization. 2023. “Investigation of Acute Kidney Injury in Children in Indonesia: Results and Regulatory Actions.” 1 March 2023. https://www.who.int/indonesia/news/detail/01-03-2023-investigation-of-acute-kidney-injury-in-children-in-indonesia--results-and-regulatory-actions.

Indonesia. Undang-Undang Nomor 8 Tahun 1999 tentang Perlindungan Konsumen.

Indonesia. Undang-Undang Nomor 17 Tahun 2023 tentang Kesehatan.

Indonesia. Peraturan Pemerintah Nomor 72 Tahun 1998 tentang Pengamanan Sediaan Farmasi dan Alat Kesehatan.

Badan Pengawas Obat dan Makanan. Peraturan BPOM Nomor 14 Tahun 2022 tentang Penarikan dan Pemusnahan Obat yang Tidak Memenuhi Standar dan/atau Persyaratan Keamanan, Khasiat, Mutu, dan Label.

Mahkamah Agung Republik Indonesia. Peraturan Mahkamah Agung Nomor 1 Tahun 2002 tentang Acara Gugatan Perwakilan Kelompok. (Mahkamah Agung RI, 2002)

Downloads

Published

14-11-2026

How to Cite

ANALISIS TANGGUNG JAWAB HUKUM PRODUSEN TERHADAP KERUGIAN KONSUMEN AKIBAT PEREDARAN OBAT SIRUP YANG TIDAK MEMENUHI PERSYARATAN KEAMANAN (STUDI KASUS PUTUSAN NOMOR 771/Pdt.G/2022/PN.Jkt.Pst). (2026). Jurnal Riset Multidisiplin Edukasi, 3(11), 207-222. https://doi.org/10.71282/jurmie.v3i11.2706

Most read articles by the same author(s)

Similar Articles

191-200 of 245

You may also start an advanced similarity search for this article.